← All trials
NCT02973503
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2016
- Primary completion
- Oct 1, 2017
- Completion date
- Oct 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University Clermont AuvergneLead sponsor
- MerckCollaborator
- University of AntwerpOverall official - principal investigator
- University of Franche-ComtéOverall official - principal investigator
- CH PERPIGNANOverall official - principal investigator
- CHU Henri MondorOverall official - principal investigator
- University of NantesOverall official - principal investigator
- University of LimogesOverall official - principal investigator
- EurofinsCollaborator
- University of MontpellierOverall official - principal investigator
- University Clermont AuvergneOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.